We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

74 hedge funds and large institutions have $61.9M invested in CytomX Therapeutics in 2024 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 24 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 24

0.74% less ownership

Funds ownership: 65.79% → 65.05% (-0.74%)

16% less funds holding

Funds holding: 88 → 74 (-14)

30% less call options, than puts

Call options by funds: $30K | Put options by funds: $43K

36% less capital invested

Capital invested by funds: $97.1M → $61.9M (-$35.3M)

52% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 27

Holders
74
Holders Change
-14
Holders Change %
-15.91%
% of All Funds
1.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
29
Reduced
24
Closed
27
Calls
$30K
Puts
$43K
Net Calls
-$13K
Net Calls Change
-$356K

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$12.5M
2
TCM
Tang Capital Management
California
+$2.67M
3
RI
RTW Investments
New York
+$2.39M
4
Millennium Management
Millennium Management
New York
+$2.34M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.99M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$7.73M
2
SCM
Sio Capital Management
New York
-$3.48M
3
BI
BVF Inc
California
-$2.72M
4
BCM
Bronte Capital Management
Australia
-$1.98M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
76
Bronte Capital Management
Australia
– -$1.98M -906,157 Closed
BC
77
BIT Capital
Germany
– -$547K -250,910 Closed
CC
78
Clearline Capital
New York
– -$429K -196,583 Closed
Man Group
79
Man Group
United Kingdom
– -$417K -191,060 Closed
Citigroup
80
Citigroup
New York
– -$270K -123,653 Closed
Bank of Montreal
81
Bank of Montreal
Ontario, Canada
– -$238K -107,700 Closed
PAS
82
Point72 Asia (Singapore)
Singapore
– -$190K -87,226 Closed
Walleye Capital
83
Walleye Capital
New York
– -$187K -85,638 Closed
YIH
84
Y-Intercept (HK)
Hong Kong
– -$121K -55,595 Closed
Marshall Wace
85
Marshall Wace
United Kingdom
– -$114K -52,289 Closed
Tudor Investment Corp
86
Tudor Investment Corp
Connecticut
– -$95.6K -43,865 Closed
JF
87
Jump Financial
Illinois
– -$84.1K -38,578 Closed
OAC
88
OMERS Administration Corp
Ontario, Canada
– -$77.2K -35,400 Closed
Balyasny Asset Management
89
Balyasny Asset Management
Illinois
– -$69.6K -31,921 Closed
SG Americas Securities
90
SG Americas Securities
New York
– -$57K -26,114 Closed
CAS
91
CTC Alternative Strategies
Illinois
– -$41.2K -18,900 Closed
Mackenzie Financial
92
Mackenzie Financial
Ontario, Canada
– -$39.5K -18,138 Closed
BHCM
93
Brevan Howard Capital Management
Jersey
– -$39.4K -18,056 Closed
HF
94
HRT Financial
New York
– -$36K -16,831 Closed
ECM
95
ExodusPoint Capital Management
New York
– -$24K -11,049 Closed
D.E. Shaw & Co
96
D.E. Shaw & Co
New York
– -$23.6K -10,811 Closed
Vontobel Holding
97
Vontobel Holding
Switzerland
– -$21.8K -10,000 Closed
Macquarie Group
98
Macquarie Group
Australia
– -$2 -1,134 Closed
Wells Fargo
99
Wells Fargo
California
– -$1.14K -524 Closed
OPTFSNA
100
Old Point Trust & Financial Services N A
Virginia
– -$545 -250 Closed
1 2 3
4
5

CTMX Hedge Fund Activity: Q2 2024 in Review

74 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2024, worth a combined $61.9M — down 36% from $97.1M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of CTMX and 13 opened new positions — a net loss of 14 holders — while 24 trimmed existing stakes and 29 added.

The largest buyer was Janus Henderson Group, opening a new position worth an estimated $12.5M. The largest seller was OrbiMed, exiting entirely with an estimated $7.73M sold.

  • 74 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2024, down from 88 in Q1 2024.
  • Funds reported $61.9M of CytomX Therapeutics stock for Q2 2024, down 36% quarter-over-quarter.
  • 13 funds opened new CytomX Therapeutics positions in Q2 2024 and 27 closed out, a net change of -14 holders.
  • The largest CytomX Therapeutics buyer in Q2 2024 was Janus Henderson Group, an estimated $12.5M added.
  • The largest CytomX Therapeutics seller in Q2 2024 was OrbiMed, an estimated $7.73M sold.

Based on aggregated 13F filings for Q2 2024.